젠탈리스 파마슈티컬스, Inc.
US ˙ NasdaqGM ˙ US98943L1070

SecurityZNTL / Zentalis Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership23,218 shares
Latest Disclosed Value $ 26,932
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 75.64% decrease in ownership of ZNTL / Zentalis Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 23,218 shares of Zentalis Pharmaceuticals, Inc. (US:ZNTL) valued at $26,933 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 95,310 shares of Zentalis Pharmaceuticals, Inc.. This represents a change in shares of -75.64% during the quarter. The current value of the position is $84,978 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 23,218 -72,092 -75.64 27 -82.78 0.0006
2025-05-28 2025-03-31 NP Zentalis Pharmaceuticals EC US98943L1070 95,310 0 0.00 152 -47.57 0.0036
2025-02-25 2024-12-31 NP Zentalis Pharmaceuticals EC US98943L1070 95,310 -13,751 -12.61 289 -28.18 0.0063
2024-11-26 2024-09-30 NP Zentalis Pharmaceuticals EC US98943L1070 109,061 508 0.47 401 -9.48 0.0076
2024-08-26 2024-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 108,553 4,509 4.33 444 -72.97 0.0090
2024-05-28 2024-03-31 NP Zentalis Pharmaceuticals EC US98943L1070 104,044 -3,353 -3.12 1,640 0.74 0.0342
2024-02-26 2023-12-31 NP Zentalis Pharmaceuticals EC US98943L1070 107,397 8,549 8.65 1,627 -17.91 0.0347
2023-11-28 2023-09-30 NP Zentalis Pharmaceuticals EC US98943L1070 98,848 13,962 16.45 1,983 -17.21 0.0517
2023-08-25 2023-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 84,886 8,958 11.80 2,395 83.45 0.0568
2023-05-26 2023-03-31 NP Zentalis Pharmaceuticals EC US98943L1070 75,928 2,257 3.06 1,306 -12.00 0.0348
2023-02-24 2022-12-31 NP Zentalis Pharmaceuticals EC US98943L1070 73,671 -267 -0.36 1,484 -7.37 0.0408
2022-11-25 2022-09-30 NP Zentalis Pharmaceuticals EC US98943L1070 73,938 13,738 22.82 1,601 -5.32 0.0459
2022-08-25 2022-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 60,200 3,451 6.08 1,692 -35.41 0.0467
2022-05-26 2022-03-31 NP Zentalis Pharmaceuticals EC US98943L1070 56,749 940 1.68 2,618 -44.19 0.0610
2022-02-25 2021-12-31 NP Zentalis Pharmaceuticals EC US98943L1070 55,809 1,715 3.17 4,691 30.16 0.1017
2021-11-24 2021-09-30 NP Zentalis Pharmaceuticals EC US98943L1070 54,094 3,872 7.71 3,605 34.93 0.0794
2021-08-26 2021-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 50,222 6,522 14.92 2,672 40.88 0.0573
2021-05-27 2021-03-31 NP Zentalis Pharmaceuticals EC US98943L1070 43,700 -979 -2.19 1,896 -18.28 0.0430
2021-02-25 2020-12-31 NP Zentalis Pharmaceuticals EC US98943L1070 44,679 27,255 156.42 2,321 307.73 0.0595
2020-11-25 2020-09-30 NP Zentalis Pharmaceuticals EC US98943L1070 17,424 0 0.00 570 -31.94 0.0183
2020-08-27 2020-06-30 NP Zentalis Pharmaceuticals EC US98943L1070 17,424 17,424 837 0.0273
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.